Please login to the form below

Not currently logged in
Email:
Password:

asthma

This page shows the latest asthma news and features for those working in and with pharma, biotech and healthcare.

Lilly expands dermatology portfolio with $1.1bn Dermira deal

Lilly expands dermatology portfolio with $1.1bn Dermira deal

Roche had been developing lebrikizumab as a potential treatment for severe asthma, but after the drug produced disappointing results in that indication decided to sell it on.

Latest news

More from news
Approximately 60 fully matching, plus 475 partially matching documents found.

Latest Intelligence

  • Growing up as a patient is hard to manage Growing up as a patient is hard to manage

    For example, studies show that approximately 38% of adolescents with epilepsy are non-adherent, whereby this increases to approximately 50% of adolescents with asthma reported as failing to take prescribed doses

  • The long and winding road to asthma breakthroughs The long and winding road to asthma breakthroughs

    a therapy targeted at a subtype representing around 10% of the asthma population. ... and adults under the age of 45 living with asthma in Europe and approximately 10% of those adults suffer severe and life- threatening symptoms.

  • Three steps forward, four steps back Three steps forward, four steps back

    In the UK, asthma hospitalises someone every seven minutes and every ten seconds someone has a potentially life-threatening asthma attack. ... asthma reduction tips, symptom logs and alternative behaviours are pivotal to improving these reviews.

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    up innate immune responses, and Cancer Research UK is repurposing an AZ chemokine CCR4 receptor drug (AZD2098) originally developed for asthma in kidney cancer.

More from intelligence
Approximately 3 fully matching, plus 38 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 23 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics